The pandemic is having a devastating impact on America’s seniors. The Medicare Part D prescription drug program provides our nation’s seniors with affordable drug coverage, which is more important now than ever. However, the Administration would threaten to destabilize the Medicare Part D program by dramatically increasing premiums for the vast majority of Part D enrollees.
The White House should abandon the Executive Order on rebates that would gut tools used for negotiating lower drug costs.
Read the results from the new Public Sector Healthcare Roundtable Survey
State Health Plans Use Drug Rebates to Lower Premiums and Enhance Benefits
All 10 surveyed state plan sponsors reported that prescription drug rebates are passed back to the plans and are used to lower enrollee premiums. Without exception, prescription drug rebates are used by plan sponsors to REDUCE COSTS AND ENHANCE BENEFITS for enrollees.
See Results from the Employer Rebate Survey
Impact of Medicare Part D Drug Manufacturer Rebates at the Point-of-Sale
How Point-of-Sale Manufacturer Rebates Could Affect Stakeholder Costs
A new report by Milliman shows that over the 10-year period 2022-2031, if all manufacturer rebates were reflected at the point-of-sale in Medicare Part D, total beneficiary premiums could increase by an estimated $28.7 billion (16%) and total Federal government spending could increase by an estimated $59.5 billion.
Read Report on Point-of-Sale Rebates
